Treatment of Pediculosis (Head Lice) in Senegal

Pediculoses Clinical Trial

— IVERAZITH  

Official title:

Study of the Therapeutic Efficacy of the Combination Azithromycin + Ivermectin in the Treatment of Pediculosis in Senegal (IVERAZITH)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03578679
• Other study ID #: SEN17/16
• Status: Completed
• Phase: N/A
• Start date: July 11, 2018
• Est. completion date: February 24, 2019

Study information

• Verified date: July 2018
• Source: Institut de Recherche pour le Developpement
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective single-arm interventional study evaluating Therapeutic efficacy of a combination of two pharmaceutical drugs, Azithromycin (AZIT) and Ivermectin (IVER) administered orally in the treatment of head lice infestations. In case of persistence of lice and / or nits on day 7, a second oral administration of combination Azithromycin + Ivermectin will be considered.

The duration of the study period is 4 months, ie 1 month and ½ of inclusion and 2 months and ½ feedback. There will be a site initiation visit "site initiation visit" before inclusions at D-7, two monitoring visits and a closing visit "close out visit" at the end of the follow-up at 4 months.

Description:

The investigators will perform a clinical trial of efficacy, single-arm, until D28 from volunteer subjects infested with head lice.

The two villages of the study (Dielmo and Ndiop) will be visited to explain the protocol and obtain community permission to work on it. Schools will also be visited to inform teachers and explain the protocol. The search for lice will be done by village women recruited for this purpose. A systematic census by family will be performed. A clinical examination of the hair will detect the persons infested with lice. On D-1, individual informed consent (an assent for participants between the ages of 15 and 18) will be systematically obtained before inclusion.

At D1, an interview and a complete clinical examination will be done on each subject consenting. All volunteers meeting the inclusion criteria will be taken on a single arms. For each voluntary participant selected fasting 1 hour before, the treatments will be administered by the investigators of the study. After taking the AZIT + IVER dose, each treated volunteer will be followed for 1 hour to observe the appearance of any side effects, then a breakfast will be offered. Head lice and nits will be searched on D1, D7, D15 and D28 for each volunteer and the hair taken on D2, D5, D7, D15 and D28. Possibly, before each treatment, Stool samples will be taken systematically on day 1 and after treatment on day 15 at any participant infested with head lice to identify intestinal parasites (load parasite in helminthiasis) to evaluate also the efficacy of ivermectin on these parasites. Sociodemographic, clinical, dose and type of material taken biological will be documented. Data on co-infections (body lice, Sarcoptes scabeii) will also be collected and reported on the study register. Each volunteer will have an identification number (ID). Only, the principal investigator, the coordinator and the investigators can access sensitive information if they exist. Data will be entered immediately by a data entry agent. The investigators will sleep on the sites and will face possible cases of effects undesirable. Regular visits will be scheduled on D2, D5, D7, D15 and D28. A clinical monitor will stay with the team on the field of D2, D5, D7, D15 and D28. A Clinical Research Organisation (CRO) will ensure the external monitoring of the study (1 site initiation visit, 2 monitoring visits and 1 visit closing of the test). It will also be scheduled for a visit by Comité National d'Ethique en Santé (CNERS) members on the field according to their schedule. All willing participants and completing the eligibility criteria for entry into this study, will be taken on a single treatment arm Azithromycin-Ivermectin in orodispersible tablets. The evaluation of the answer therapy will be done on D7 and / or D15.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 450
• Est. completion date: February 24, 2019
• Est. primary completion date: January 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 6 Years and older

Eligibility

Includes lists of Inclusion Criteria:

• body weight = 15 kg for oral administration to ivermectin, • Obtain the signed informed consent of the parent or caregiver for his participation in the study.

Includes lists of Criteria Exclusion:

• Refusal of participation,

• Non-residents in the villages during the study period,

• body weight <15 kg not eligible for oral administration with ivermectin,

• Pregnant women, who in the context of the daily medical and epidemiological monitoring of the population of Dielmo-like that of Ndiop- are identified and very early at the looking at the first signs of conception in a pregnant woman from her state of pregnancy on the basis of a proven test. In addition, before any treatment with ivermectin, will be systematically requested from each of the target women of reproductive age if she is pregnant

• Women breastfeeding at the time of the study,

Related Conditions & MeSH terms

• Lice Infestations
• Pediculoses

Intervention

Drug:
• Ivermectin Oral Product
treatment of pediculosis (head lice)

Locations

Country	Name	City	State
Senegal	Institut de Recherche pour le Developpement	Dakar

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Recherche pour le Developpement

Country where clinical trial is conducted

Senegal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Parasiticidal efficacy: disappearance of head lice (zero lice) on day 7	Evaluating the efficacy of the treatment of combination of two usual drugs from volunteer subjects infested with head lice.; To study the therapeutic efficacy of the combination Azithromycin-Ivermectin administered orally in the treatment of head lice infestations (in case of persistence of lice at D7 a second oral administration of the combination azithromycin-Ivermectin will be considered).	Day 7